Chemoproteomic Selectivity Profiling of PIKK and PI3K Kinase Inhibitors

Citations Over TimeTop 13% of 2019 papers

Abstract

Chemical proteomic approaches utilizing immobilized, broad-selective kinase inhibitors (Kinobeads) have proven valuable for the elucidation of a compound's target profile under close-to-physiological conditions and often revealed potentially synergistic or toxic off-targets. Current Kinobeads enrich more than 300 native protein kinases from cell line or tissue lysates but do not systematically cover phosphatidylinositol 3-kinases (PI3Ks) and phosphatidylinositol 3-kinase-related kinases (PIKKs). Some PIKKs and PI3Ks show aberrant activation in many human diseases and are indeed validated drug targets. Here, we report the development of a novel version of Kinobeads that extends kinome coverage to these proteins. This is achieved by inclusion of two affinity probes derived from the clinical PI3K/MTOR inhibitors Omipalisib and BGT226. We demonstrate the utility of the new affinity matrix by the profiling of 13 clinical and preclinical PIKK/PI3K inhibitors. The large discrepancies between the PI3K affinity values obtained and reported results from recombinant assays led us to perform a phosphoproteomic experiment showing that the chemoproteomic assay is the better approximation of PI3K inhibitor action in cellulo. The results further show that NVP-BEZ235 is not a PI3K inhibitor. Surprisingly, the designated ATM inhibitor CP466722 was found to bind strongly to ALK2, identifying a new chemotype for drug discovery to treat fibrodysplasia ossificans progressiva.

Related Papers

• → Assessment of Chemical Coverage of Kinome Space and Its Implications for Kinase Drug Discovery(2008)161 cited
• → The Current Status of Drug Discovery Against the Human Kinome(2009)81 cited
• → Chemogenomic Analysis of the Druggable Kinome and Its Application to Repositioning and Lead Identification Studies(2019)23 cited
• → An innovative kinome platform to accelerate small-molecule inhibitor discovery and optimization from hits to leads(2021)7 cited
• → Integration of Synthetic Organic Chemistry and <i>in silico</i> Drug Discovery - Lead Discovery of Renin Inhibitors and <i>O</i>-GlcNAcase Inhibitors(2023)1 cited